Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

Figures & data

Figure 1 Patient disposition: (A) Cumulative proportion of patients (B) Biologic-naïve and biologic-experienced patients. (C) HLA-Cw6–negative and HLA-Cw6–positive patients. *Data from patients deceased during the SUPREME study (n=8) were included.

Abbreviations: HLA, human leucocyte antigen; n, number of patients.

Table 1 Baseline Demographics and Disease Characteristics

Characteristic	HLA-Cw6 Positive (N=128)	HLA-Cw6 Negative (N=166)	Overall Patient Cohort^† (N=297)
Age (years)	42.8±13.7	48.5±13.0	P < 0.001
			45.9±13.5
Age categories (years), n (%)			P = 0.521
<65	117 (91.4)	148 (89.2)	268 (90.2)
≥65	11 (8.6)	18 (10.8)	29 (9.8)
Sex, n (%)			P = 0.358
Male	87 (68.0)	121 (72.9)	210 (70.7)
Female	41 (32.0)	45 (27.1)	87 (29.3)
Race, n (%)			P = 1.000
Caucasian	128 (100.0)	162 (97.6)	293 (98.7)
Weight (kg)	77.5±15.1	83.9±17.8	P < 0.001
			81.2±17.0
Height (cm)	171.9±9.1	171.6±9.4	P = 0.791
			171.6±9.2
BMI categories (kg/m^2), n (%)			P = 0.013
<25	54 (42.2)	47 (28.3)	101 (34.0)
≥25	74 (57.8)	119 (71.7)	196 (66.0)
Waist circumference (cm), n	116	158	277 (P < 0.001)
	92.7±13.9	99.7±16.0	96.9±15.6
Smoking status, n (%)			P = 0.060
Never	42 (32.8)	74 (44.6)	118 (39.7)
Current	68 (53.1)	65 (39.2)	133 (44.8)
Former	18 (14.1)	27 (16.3)	46 (15.5)
Absolute PASI	21.0±9.1	22.5±10.9	21.9±10.2
Type of psoriasis history at diagnosis, n (%)
Nail psoriasis	46 (35.9)	65 (39.2)	113 (38.1)
Scalp psoriasis	95 (74.2)	133 (80.1)	231 (77.8)
Age at diagnosis of psoriasis (years)	23.6±13.1	31.1±14.5	27.8±14.4
Time since first diagnosis of psoriasis (years), n	128	166	297
	19.7±12.4	17.9±11.5	18.7±11.9
Number of patients with psoriatic arthritis, n (%)	21 (16.4)	40 (24.1)	62 (20.9)
Type of psoriatic arthritis, n (%)
Polyarticular	19 (14.8)	33 (19.9)	53 (17.9)
Monoarticular	1 (0.8)	4 (2.4)	5 (1.7)
Axial	4 (3.1)	7 (4.2)	11 (3.7)
Enthesitis	4 (3.1)	6 (3.6)	10 (3.4)
Dactylitis	7 (5.5)	8 (4.8)	15 (5.1)
Time since first diagnosis of psoriatic arthritis (years), n	20	39	60
	8.4±8.3	10.8±9.4	9.8±9.1

Notes: P-values for categorical variables were calculated using the chi-square test or Fisher exact test and those for continuous variables were calculated using the t-test. The data are mean±SD unless specified otherwise. ^†Three patients with missing HLA-Cw6 assessments are included in the “overall patient cohort” column.

Abbreviations: BMI, body mass index; HLA, human leucocyte antigen; N, number of patients in the population; n, number of patients; PASI, Psoriasis Area and Severity Index; SD, standard deviation.

Figure 2 Proportion of patients still on treatment with secukinumab after 42 months: (A) Cumulative proportion of patients. (B) Biologic-naïve and biologic-experienced patients. (C) HLA-Cw6–positive and HLA-Cw6–negative patients.

Figure 3 Proportion of patients with a PASI90 response over time: (A) Cumulative proportion of patients. (B) Biologic-naïve and biologic-experienced patients.

Abbreviation: PASI, Psoriasis Area and Severity Index.

Figure 4 Mean values of the absolute PASI scores over time: (A) Cumulative proportion of patients. (B) Biologic-naïve and biologic-experienced patients. (C) HLA-Cw6–negative and HLA-Cw6–positive patients.

Abbreviation: PASI, Psoriasis Area and Severity Index.

Figure 5 Mean values of DLQI over time: (A) Cumulative proportion of patients. (B) Biologic-naïve and biologic-experienced patients. (C) HLA-Cw6–negative and HLA-Cw6–positive patients.

Abbreviation: DLQI, Dermatology Life Quality Index.

Table 2 Patients with AEs and SAEs Leading to Discontinuation of the Study Drug

n (%)	Overall Patient Cohort N=297
AEs	226 (76.1)
SAEs	48 (16.2)
AE related to the study drug	72 (24.2)
AE leading to study drug discontinuation	17 (5.7)
Stomatitis	1 (0.3)
Large intestine polyp	1 (0.3)
Colitis ulcerative	1 (0.3)
Rash pustular	2 (0.7)
Upper respiratory tract infection	1 (0.3)
Respiratory tract infection	1 (0.3)
Infusion-related reaction	1 (0.3)
Psoriatic arthropathy	1 (0.3)
Lung neoplasm malignant	1 (0.3)
Breast cancer	1 (0.3)
Major depression	1 (0.3)
Pulmonary mass	1 (0.3)
Psoriasis	2 (0.7)
Papule	1 (0.3)
Dermatitis exfoliative	1 (0.3)
Dermatitis atopic	1 (0.3)
Skin exfoliation	1 (0.3)
Hypertension	1 (0.3)
SAE leading to study drug discontinuation	5 (1.7)
Colitis ulcerative	1 (0.3)
Lung cancer	1 (0.3)
Breast cancer	1 (0.3)
Major depression	1 (0.3)
Pulmonary mass	1 (0.3)

Abbreviations: AE, adverse event; N, number of patients in the study cohort; n, number of patients with at least one AE in the category; SAE, serious AE.